DOCSLIB.ORG

Outcomes in Autoimmune Retinopathy Patients Treated with Rituximab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outcomes in Autoimmune Retinopathy Patients Treated with Rituximab Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab SAMANEH DAVOUDI, NAZANIN EBRAHIMIADIB, CAGLA YASA, DAMLA D. SEVGI, RAMAK ROOHIPOOR, EVANGELIA PAPAVASILIEOU, JASON COMANDER, AND LUCIA SOBRIN PURPOSE: To evaluate clinical and ancillary testing, UTOIMMUNE RETINOPATHY (AIR) RESULTS FROM A including adaptive optics, outcomes in autoimmune presumed immunologic attack on the retina by retinopathy (AIR) patients treated with rituximab. antibodies against retinal antigens. The spectrum A DESIGN: Retrospective, interventional case series. of AIR includes nonparaneoplastic AIR (npAIR), METHODS: PATIENTS: Sixteen AIR patients treated with cancer-associated retinopathy (CAR), melanoma- rituximab. OBSERVATION PROCEDURES: All patients were associated retinopathy (MAR), and autoimmune-related treated with a loading and maintenance dose schedule of retinopathy and optic neuropathy (ARRON). There is intravenous rituximab. Visual acuity (VA), electroreti- no established treatment protocol for AIR, and the nography (ERG), and spectral-domain optical coherence evidence base for therapeutic intervention includes only tomography (SDOCT) and visual field (VF) results a few retrospective case series and case reports.1 The largest were recorded. A subset of patients was also imaged using retrospective series assessed therapeutic effects of immuno- adaptive optics scanning laser ophthalmoscopy suppressive medications including cyclosporine, predni- (AO-SLO). MAIN OUTCOME MEASURES: Rates of VA sone, infliximab, azathioprine, and mycophenolate in 30 change before vs after rituximab initiation were compared consecutive patients with AIR.2 They found potential ben- with mixed-model linear regression. efits from using immunosuppression to treat AIR, but this RESULTS: The rate of visual decline was significantly series did not include any patients treated with rituximab. less after rituximab initiation compared with the rate of Given the proposed antibody-mediated nature of AIR, a visual decline prior to rituximab initiation (P [ .005). therapeutic agent that targets B cells and thus reduces sys- Seventy-seven percent of eyes had stable or improved temic antibody levels would seem reasonable. Rituximab is VA 6 months after rituximab initiation. Amplitudes a monoclonal antibody that targets CD20þ Bcells.This and implicit times on ERG, mean deviation on VF, central medication has Food and Drug Administration approval subfield mean thickness, and total macular volume did not for treatment of several rheumatologic and hematologic dis- decrease to a significant degree over the rituximab eases.3 There are 6 individual case reports that have treatment period. Six eyes had serial AO-SLO imaging. described the treatment of AIR with rituximab, with varying Cone densities did not change significantly over the levels of success.3–8 These 6 patients include 1 patient with treatment period. npAIR in the setting of systemic lupus erythematosus and 5 3–8 CONCLUSION: VA was stable or improved in a majority patients with CAR. The primary aim of the current study of AIR patients while they were being treated with ritux- is to report outcomes for the treatment of AIR with imab. OCT and ERG parameters, as well as AO-SLO rituximab in a larger, consecutive series of patients. cone densities, were stable during treatment. Studies A secondary aim of the study is to report on the use of with additional patients and longer follow-up periods adaptive optics scanning laser ophthalmoscopy are needed to further explore the utility of rituximab in (AO-SLO) to monitor AIR. Patients with AIR often do the management of AIR. (Am J Ophthalmol not have visible retinal pathology that can be monitored 2017;180:124–132. Ó 2017 Elsevier Inc. All rights to judge progression and response to treatment. Therefore, reserved.) ancillary testing including electroretinography (ERG), visual field (VF), and spectral-domain optical coherence tomography (SDOCT) are typically used to monitor AIR patients.9 However, some patients present with advanced Supplemental Material available at AJO.com. disease and sparing of function in only a small area of See Accompanying Editorial Article on page xv. retina centrally. These patients have severely reduced Accepted for publication Apr 26, 2017. ERGs and VFs at baseline as well as OCTs with only a From the Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts (S.D., N.E., small amount of intact ellipsoid zone. It is difficult to judge C.Y., D.D.S., R.R., E.P., J.C., L.S.); and Department of Ophthalmology, progression in these cases. AO-SLO is a new technique Farabi Eye Hospital, Eye Research Center, Tehran University of that allows for quantitation of the central photoreceptors Medical Sciences, Tehran, Iran (N.E., R.R.). 10 Inquiries to Lucia Sobrin, Massachusetts Eye and Ear Infirmary, 243 that remain in these patients, and thus has the potential Charles St, Boston, MA 02114; e-mail: [email protected] to be a useful tool to monitor patients with AIR. There is 124 © 2017 ELSEVIER INC.ALL RIGHTS RESERVED. 0002-9394/$36.00 http://dx.doi.org/10.1016/j.ajo.2017.04.019 1 case report of a patient with MAR in whom adaptive function, hepatitis B and C, tuberculosis, and complete optics imaging was used to detect cone density reduction blood counts before starting rituximab. before any detectable structural changes on SDOCT at Two different loading regimens of rituximab were used. the time of initial diagnosis,11 but this is the first study From 2010 to 2014, all patients were treated with a loading in which AO-SLO has been used to monitor AIR patients regimen of 1000 mg every other week for 2 doses, which is longitudinally. the most common dose used for rheumatologic conditions. More recently, we used a loading dose of 375 mg/m2 (eg, 675 mg for a 1.8 m2 body surface area) weekly for 4 weeks. This dose is used more commonly for hematologic malignancies, and we switched to this dosing based on METHODS encouraging results from 2 patients treated with this regimen. Treatment was repeated every 6 months, or PARTICIPANTS: This retrospective case series was sooner if the patient had worsening of symptoms earlier. approved by the Massachusetts Eye and Ear Infirmary The rationale for regular retreatment every 6 months in (MEEI) Institutional Review Board and was compliant the absence of worsening symptoms is that the peripheral with the Health Insurance Portability and Accountability CD20þ B cells begin to recover about 6–9 months after Act. We reviewed the medical records of all AIR patients rituximab infusion.12 Retreatment consisted of 1 rituximab who were examined on the MEEI Retina/Uveitis Services 1000 mg infusion. Patients were monitored with CD20 sub- from 2010 to 2016 and were treated with rituximab. The sets, complete blood counts, liver function tests, and a com- diagnosis was based on characteristic symptoms (sudden plete metabolic profile at each infusion and every 3 months or subacute painless loss of vision, photopsias, scotomas, between infusions. Total immunoglobulin levels were photoaversion, nyctalopia) and findings, abnormal ERG monitored every 6 months. Side effects were recorded at findings including abnormal rod and/or cone responses on each visit. Some patients were treated with rituximab as full-field testing and/or any abnormality on multifocal monotherapy. Others had rituximab added to other immu- testing, presence of antiretinal antibodies, exclusion of nosuppression. Intravenous methylprednisolone sodium other diagnoses, absence of overt inflammation, and no his- succinate 100 mg and hydroxyzine 25 mg were given as tory of hereditary retinal disease.9 An evaluation for malig- part of the pretreatment regimen before each rituximab nancy was done for all patients who did not already have a infusion to decrease the chance of infusion reactions. diagnosis of cancer. All patients had blood sent for antire- tinal antibody testing by Western blot to the Ocular Immu- ASSESSMENT OF QUANTITATIVE AND QUALITATIVE nology Laboratory, Casey Eye Institute, Oregon Health and CHARACTERISTICS IN OPTICAL COHERENCE TOMOGRA- Science University. Snellen visual acuity (VA), visual PHY: SDOCT images were obtained every 3 months. symptoms, ERG, fundus autofluorescence, VF, and Central subfield mean thickness (CSMT) and total macu- SDOCT results were recorded. OCT imaging was lar volume (TMV) were recorded from each visit from a performed with an SDOCT instrument (Spectralis, Heidel- horizontal foveal scan image. They were measured within berg, Germany). Fovea-centered images were acquired (25 the central 1-mm-diameter circle surrounding the fovea lines within a 20-degree horizontal scan and 25 lines within and the central 6-mm-diameter circle surrounding the a 20-degree vertical scan). Full-field ERGs were performed fovea, respectively. A masked ophthalmologist-grader with Burian-Allen electrodes (Hansen Labs, Coralville, ensured that the scans from which CSMT and TMV Iowa, USA) according to International Society for Clinical were recorded were of good quality and without artifact. Electrophysiology of Vision standard protocols. Multifocal electroretinography was performed with the Veris instru- FULL-FIELD AND MULTIFOCAL ELECTRORETINOG- ment (Electro-Diagnostic Imaging, Burlingame, Califor- RAPHY: Full-field and multifocal electroretinography nia, USA) and a stimulus array of 103 hexagons. A were obtained every 6 months. For the full-field electroret- subset of patients was also imaged using a prototype
Load more

Recommended publications
  • Diagnosis and Treatment of Paraneoplastic Syndromes 1
    Instructions: • Each speaker will prepare a syllabus that must be submitted through the online submission system. • The length of the syllabus will be no shorter than 4 single spaced pages in essay (not point) format, plus references. • Use single spaced, 11 point type and (if possible) Times New Roman font. • When typing the text use word wrap, not hard returns to determine your lines. • If headings and subheadings are used, these may be highlighted by using all caps and bold. • Do not use the header or footer feature or endnotes in preparing the text. • The submission must be submitted online. Title: Diagnosis and Treatment of Paraneoplastic Syndromes Learning Objectives: 1. Describe the spectrum of paraneoplastic syndromes with neuro-ophthalmic features 2. Define the challenges in diagnosis of the paraneoplastic syndromes 3. Explain the therapeutic options for treatment of these diseases CME Questions: 1. The presence of serum antibodies against recoverin a. are pathognomonic for CAR b. are found in the majority of patients with lung cancer c. may be responsible apoptotic cell death in CAR patients d. are best detected by immunofluorescent studies on retina 2. Which of the following is correct regarding therapy for paraneoplastic neuro-ophthalmic disease: a. steroid therapy may be helpful in control of disease b. should be initiated only after there is validation for the presence of autoreactive antibodies c. cytoreduction of the primary tumor is not helpful in controlling the autoimmune component d. biologic immunomodulatory agents have no role in therapy 3. Lambert-Eaton myasthenic syndrome is associated with which of the following: a.
    [Show full text]
  • Autoantibody Profiles and Clinical Association in Thai Patients With
    www.nature.com/scientificreports OPEN Autoantibody profles and clinical association in Thai patients with autoimmune retinopathy Aulia Rahmi Pawestri1,8, Niracha Arjkongharn2,8, Ragkit Suvannaboon2,3,8, Aekkachai Tuekprakhon2,4, Vichien Srimuninnimit5, Suthipol Udompunthurak6, La‑ongsri Atchaneeyasakul2, Ajchara Koolvisoot7* & Adisak Trinavarat2* Autoimmune retinopathy (AIR) is a rare immune‑mediated infammation of the retina. The autoantibodies against retinal proteins and glycolytic enzymes were reported to be involved in the pathogenesis. This retrospective cohort study assessed the antiretinal autoantibody profles and their association with clinical outcomes of AIR patients in Thailand. We included 44 patients, 75% were females, with the overall median age of onset of 48 (17–74, IQR 40–55.5) years. Common clinical presentations were nyctalopia (65.9%), blurred vision (52.3%), constricted visual feld (43.2%), and nonrecordable electroretinography (65.9%). Underlying malignancy and autoimmune diseases were found in 2 and 12 female patients, respectively. We found 41 autoantibodies, with anti‑α‑enolase (65.9%) showing the highest prevalence, followed by anti‑CAII (43.2%), anti‑aldolase (40.9%), and anti‑GAPDH (36.4%). Anti‑aldolase was associated with male gender (P = 0.012, OR 7.11, 95% CI 1.54– 32.91). Anti‑CAII showed signifcant association with age of onset (P = 0.025, 95% CI − 17.28 to − 1.24), while anti‑α‑enolase (P = 0.002, OR 4.37, 95% CI 1.83–10.37) and anti‑GAPDH (P = 0.001, OR 1.87, 95% CI 1.32–2.64) were signifcantly associated with nonrecordable electroretinography. Association between the antibody profles and clinical outcomes may be used to direct and adjust the treatment plans and provide insights in the pathogenesis of AIR.
    [Show full text]
  • Major Review
    SURVEY OF OPHTHALMOLOGY VOLUME 48 • NUMBER 1 • JANUARY–FEBRUARY 2003 MAJOR REVIEW Paraneoplastic Retinopathies and Optic Neuropathies Jane W. Chan, MD Department of Internal Medicine, Division of Neurology, University of Nevada School of Medicine, Las Vegas, Nevada, USA Abstract. Unusual neuro-ophthalmologic symptoms and signs that go unexplained should warrant a thorough investigation for paraneoplastic syndromes. Although these syndromes are rare, these clinical manifestations can herald an unsuspected, underlying malignancy that could be treated early and aggressively. This point underscores the importance of distinguishing and understanding the various, sometimes subtle, presentations of ocular paraneoplastic syndromes. Outlined in this review article are diagnostic features useful in differentiating cancer-associated retinopathy, melanoma-associated retin- opathy, and paraneoplastic optic neuropathy. These must also be distinguished from non–cancer- related eye disorders that may clinically resemble cancer-associated retinopathy. The associated anti- bodies and histopathology of each syndrome are presented to help in the understanding of these autoimmune phenomena. Treatment outcomes from reported cases are summarized, and some poten- tial novel immunotherapies are also discussed. (Surv Ophthalmol 48:12–38, 2003. © 2003 by Else- vier Science Inc. All rights reserved.) Key words. autoimmune • cancer-associated retinopathy • melanocytic-associated retinopathy • optic neuropathy • paraneoplastic I. Cancer-Associated Retinopathy nual percent change (based on rates age-adjusted to the 2000 U.S. standard population) for invasive lung Cancer-associated retinopathy (CAR) has been Ϫ thought to be one of the most common paraneo- and bronchial cancer decreased from 3.0 to 0.9 plastic retinopathies. Its incidence is equal among from 1973 to 1999. During the same time period women and men.
    [Show full text]
  • Consensus on the Diagnosis and Management of Nonparaneoplastic Autoimmune Retinopathy Using a Modified Delphi Approach
    Consensus on the Diagnosis and Management of Nonparaneoplastic Autoimmune Retinopathy Using a Modified Delphi Approach AUSTIN R. FOX, LYNN K. GORDON, JOHN R. HECKENLIVELY, JANET L. DAVIS, DEBRA A. GOLDSTEIN, CAREEN Y. LOWDER, ROBERT B. NUSSENBLATT, NICHOLAS J. BUTLER, MONICA DALAL, THIRAN JAYASUNDERA, WENDY M. SMITH, RICHARD W. LEE, GRAZYNA ADAMUS, CHI-CHAO CHAN, JOHN J. HOOKS, CATHERINE W. MORGANS, BARBARA DETRICK, AND H. NIDA SEN PURPOSE: To develop diagnostic criteria for nonpara- second-line treatments, though a consensus agreed that neoplastic autoimmune retinopathy (AIR) through biologics and intravenous immunoglobulin were consid- expert panel consensus and to examine treatment patterns ered appropriate in the treatment of nonparaneoplastic among clinical experts. AIR patients regardless of the stage of disease. Experts DESIGN: Modified Delphi process. agreed that more evidence is needed to treat nonparaneo- METHODS: A survey of uveitis specialists in the Amer- plastic AIR patients with long-term immunomodulatory ican Uveitis Society, a face-to-face meeting (AIR Work- therapy and that there is enough equipoise to justify ran- shop) held at the National Eye Institute, and 2 iterations domized, placebo-controlled trials to determine if nonpar- of expert panel surveys were used in a modified Delphi aneoplastic AIR patients should be treated with long-term process. The expert panel consisted of 17 experts, immunomodulatory therapy. Regarding antiretinal anti- including uveitis specialists and researchers with exper- body detection, consensus agreed that a standardized tise in antiretinal antibody detection. Supermajority assay system is needed to detect serum antiretinal anti- consensus was used and defined as 75% of experts in bodies. Consensus agreed that an ideal assay should agreement.
    [Show full text]
  • Qt2mh1j0hw.Pdf
    UCLA UCLA Previously Published Works Title Consensus on the Diagnosis and Management of Nonparaneoplastic Autoimmune Retinopathy Using a Modified Delphi Approach. Permalink https://escholarship.org/uc/item/2mh1j0hw Authors Fox, Austin R Gordon, Lynn K Heckenlively, John R et al. Publication Date 2016-08-01 DOI 10.1016/j.ajo.2016.05.013 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Consensus on the Diagnosis and Management of Nonparaneoplastic Autoimmune Retinopathy Using a Modified Delphi Approach AUSTIN R. FOX, LYNN K. GORDON, JOHN R. HECKENLIVELY, JANET L. DAVIS, DEBRA A. GOLDSTEIN, CAREEN Y. LOWDER, ROBERT B. NUSSENBLATT, NICHOLAS J. BUTLER, MONICA DALAL, THIRAN JAYASUNDERA, WENDY M. SMITH, RICHARD W. LEE, GRAZYNA ADAMUS, CHI-CHAO CHAN, JOHN J. HOOKS, CATHERINE W. MORGANS, BARBARA DETRICK, AND H. NIDA SEN PURPOSE: To develop diagnostic criteria for nonpara- second-line treatments, though a consensus agreed that neoplastic autoimmune retinopathy (AIR) through biologics and intravenous immunoglobulin were consid- expert panel consensus and to examine treatment patterns ered appropriate in the treatment of nonparaneoplastic among clinical experts. AIR patients regardless of the stage of disease. Experts DESIGN: Modified Delphi process. agreed that more evidence is needed to treat nonparaneo- METHODS: A survey of uveitis specialists in the Amer- plastic AIR patients with long-term immunomodulatory ican Uveitis Society, a face-to-face meeting (AIR Work- therapy and that there is enough equipoise to justify ran- shop) held at the National Eye Institute, and 2 iterations domized, placebo-controlled trials to determine if nonpar- of expert panel surveys were used in a modified Delphi aneoplastic AIR patients should be treated with long-term process.
    [Show full text]
  • Case Report Intravenous Immunoglobulin for Management Of
    Case Report Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy Sahba Fekri1,2, MD; Masoud Soheilian1,2, MD; Babak Rahimi-Ardabili1, MD 1Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2Department of Ophthalmology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ORCID: Sahba Fekri: https://orcid.org/0000-0002-7388-6725 Abstract Purpose: To report a case of non-paraneoplastic autoimmune retinopathy (npAIR) treated with intravenous immunoglobulin (IVIG). Case report: A 12-year-old boy presented with progressive visual field loss, nyctalopia, and flashing for three months. He had suffered from common cold two weeks before the onset of these symptoms. On the basis of clinical history and paraclinical findings, he was diagnosed with npAIR, and IVIG without immunosuppressive therapy was started. During the one-year follow-up period after the first course of IVIG, flashing disappeared completely. Visual acuity remained 10/10, but nyctalopia did not improve. Multimodal imaging showed no disease progression. Conclusion: Although established retinal degenerative changes seem irreversible in npAIR, IVIG may be a suitable choice to control the disease progression. Keywords: Autoimmune Retinopathy; Intravenous Immunoglobulin; Nyctalopia; Photopsia; Retinal Degeneration J Ophthalmic Vis Res 2020; 15 (2): 246–251 INTRODUCTION retinal disorders, caused by circulating antiretinal antibodies (ARAs). They can be paraneoplastic (pAIR) or, more commonly, non-neoplastic Autoimmune retinopathies (AIRs) are a heteroge- (npAIR) characterized by bilateral, often neous group of immune-mediated degenerative asymmetric, progressive, painless visual acuity or visual field loss over weeks to months with photopsias and scotomas.[1] Depending Correspondence to: on the cell type and antigen targeted by Sahba Fekri, MD.
    [Show full text]
  • Ocular Paraneoplastic Syndromes
    biomedicines Review Ocular Paraneoplastic Syndromes Joanna Prze´zdziecka-Dołyk 1,2, Anna Brzecka 3 , Maria Ejma 4, Marta Misiuk-Hojło 1 , Luis Fernando Torres Solis 5, Arturo Solís Herrera 6, Siva G. Somasundaram 7 , Cecil E. Kirkland 7 and Gjumrakch Aliev 8,9,10,11,* 1 Department of Ophthalmology, Wroclaw Medical University, Borowska 213, 50-556 Wrocław, Poland; [email protected] (J.P.-D.); [email protected] (M.M.-H.) 2 Department of Optics and Photonics, Wrocław University of Science and Technology, Wyspia´nskiego27, 50-370 Wrocław, Poland 3 Department of Pulmonology and Lung Oncology, Wrocław Medical University, Grabiszy´nska 105, 53-439 Wrocław, Poland; [email protected] 4 Department of Neurology, Wroclaw Medical University, Borowska 213, 50-556 Wrocław, Poland; [email protected] 5 The School of Medicine, Universidad Autónoma de Aguascalientes, Aguascalientes 20392, Mexico; [email protected] 6 Human Photosynthesis© Research Centre, Aguascalientes 20000, Mexico; [email protected] 7 Department of Biological Sciences, Salem University, Salem, WV 26426, USA; [email protected] (S.G.S.); [email protected] (C.E.K.) 8 Sechenov First Moscow State Medical University (Sechenov University), St. Trubetskaya, 8, bld. 2, 119991 Moscow, Russia 9 Research Institute of Human Morphology, Russian Academy of Medical Science, Street Tsyurupa 3, 117418 Moscow, Russia 10 Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432 Moscow, Russia 11 GALLY International Research Institute, 7733 Louis Pasteur Drive, #330, San Antonio, TX 78229, USA * Correspondence: [email protected] or [email protected]; Tel.: +1-210-442-8625 or +1-440-263-7461 Received: 6 September 2020; Accepted: 8 November 2020; Published: 10 November 2020 Abstract: Ocular-involving paraneoplastic syndromes present a wide variety of clinical symptoms.
    [Show full text]
  • Autoantibody Against Transient Receptor Potential M1 Cation
    Wang et al. BMC Ophthalmology 2012, 12:56 http://www.biomedcentral.com/1471-2415/12/56 CASE REPORT Open Access Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy Yujuan Wang1,2, Mones S Abu-Asab1, Wei Li3, Mary E Aronow4, Arun D Singh4 and Chi-Chao Chan1* Abstract Background: Paraneoplastic retinopathy is caused by the cross-reaction of neoplasm-directed autoantibodies against retinal antigens and results in retinal damage. Paraneoplastic vitelliform retinopathy, a presumed paraneoplastic retinopathy with features of atypical melanoma-associated retinopathy, has recently been reported in patients with metastatic melanoma. Ocular ultrastructure and its autoantibody localization of paraneoplastic vitelliform retinopathy are still indefinable. This is the first report of anti-transient receptor potential M1 antibody directly against human retinal bipolar dendritic tips in a melanoma patient with paraneoplastic vitelliform retinopathy. Case presentation: We present a pair of postmortem eyes of an 80-year-old male with metastatic cutaneous melanoma, who developed paraneoplastic vitelliform retinopathy. The autopsied eyes were examined with light microscopy, immunohistochemistry, and transmission electron microscopy. Microscopically, the inner nuclear layer and outer plexiform layer were the most affected retinal structures, with local thinning. The lesions extended to the outer nuclear layer, resulting in focal retinal degeneration, edema, and atrophy. No active inflammation or melanoma cells were observed. Immunohistochemistry showed tightly compact bipolar cell nuclei (protein kinase C alpha/calbindin positive) with blur/loss of ON bipolar cell dendritic tips (transient receptor potential M1 positive) in diffusely condensed outer plexiform layer. The metastatic melanoma cells in his lung also showed immunoreactivity against transient receptor potential M1 antibody.
    [Show full text]
  • Title Clinical and Immunological Characterization Of
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Clinical and immunological characterization of paraneoplastic Title retinopathy. Makiyama, Yukiko; Kikuchi, Takanobu; Otani, Atsushi; Oishi, Author(s) Akio; Guo, Congrong; Nakagawa, Satoko; Ogino, Ken; Kojima, Hiroshi; Kurimoto, Masafumi; Yoshimura, Nagahisa Investigative ophthalmology & visual science (2013), 54(8): Citation 5424-5431 Issue Date 2013-08 URL http://hdl.handle.net/2433/187393 Right © Association for Research in Vision and Ophthalmology Type Journal Article Textversion author Kyoto University Clinical and Immunological Characterization of Paraneoplastic Retinopathy Short title: Characterization of Paraneoplastic Retinopathy Yukiko Makiyama,1 Takanobu Kikuchi,2 Atsushi Otani,1 Akio Oishi,1 Congrong Guo,1 Satoko Nakagawa,1 Ken Ogino,1 Hiroshi Kojima,1 Masafumi Kurimoto,1 Nagahisa Yoshimura,1 1Department of Ophthalmology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan 2Department of Instrumental Analysis Research Center for Human and Environmental Science, Shinshu Univeisity, Nagano 390-8621, Japan All correspondence should be addressed to: Atsushi Otani, MD, PhD Department of Ophthalmology, Kyoto University Graduate School of Medicine 54-Kawaharacho, Shyogoin, Sakyo-ku, Kyoto 606-8507, Japan E-mail: [email protected], Fax: +81-75-752-0933 Tel: +81-75-751-3248 1 Key words: paraneoplastic retinopathy, spectral domain-optical coherence tomography, Western blot analysis, immunohistochemistory, autoantibody, anti-retinal antibody 2 Abstract Purpose: To report the clinical and immunological characterization of paraneoplastic retinopathy and to investigate the association between spectral domain-optical coherence tomography (SD-OCT) findings and the target of autoantibodies in paraneoplastic retinopathy (PR).
    [Show full text]
  • Immune Cell Infiltration Into the Eye Is Controlled by IL-10 in Recoverin-Induced Autoimmune Retinopathy
    Immune Cell Infiltration into the Eye Is Controlled by IL-10 in Recoverin-Induced Autoimmune Retinopathy This information is current as Enayat Nikoopour, Cheng-mao Lin, Sarah Sheskey, John R. of September 28, 2021. Heckenlively and Steven K. Lundy J Immunol 2019; 202:1057-1068; Prepublished online 11 January 2019; doi: 10.4049/jimmunol.1800574 http://www.jimmunol.org/content/202/4/1057 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/01/10/jimmunol.180057 Material 4.DCSupplemental http://www.jimmunol.org/ References This article cites 39 articles, 4 of which you can access for free at: http://www.jimmunol.org/content/202/4/1057.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Immune Cell Infiltration into the Eye Is Controlled by IL-10 in Recoverin-Induced Autoimmune Retinopathy Enayat Nikoopour,*,†,‡ Cheng-mao Lin,* Sarah Sheskey,* John R.
    [Show full text]
  • Autoimmune Retinopathy: a Review Aristófanes Mendonça Canamary Jr.1* , Walter Yukihiko Takahashi2 and Juliana Maria Ferraz Sallum1
    Canamary Jr. et al. Int J Retin Vitr (2018) 4:1 https://doi.org/10.1186/s40942-017-0104-9 International Journal of Retina and Vitreous REVIEW Open Access Autoimmune retinopathy: A Review Aristófanes Mendonça Canamary Jr.1* , Walter Yukihiko Takahashi2 and Juliana Maria Ferraz Sallum1 Abstract Autoimmune retinopathy (AIR) is a rare and still poorly understood immune-mediated disease that may cause infam- mation from circulating autoantibodies against the retina. It may be related to history of autoimmune disease in the patient or in a family member or the presence of neoplastic disease in the individual. The disease may be subdivided into paraneoplastic and non-paraneoplastic AIR. When related to melanoma, it is referred to as MAR, and when related to other cancers, it is called CAR. The exact prevalence of AIR is unknown. It mainly afects older adults. Patients present with bilateral and asymmetric scotomas, photopsias, visual feld defects, with rapidly progressive visual loss in late onset. In the initial stage, fundus examination is unremarkable, and in late stages, there is limited retinal epithe- liopathy and vascular attenuation, with or without optic disc pallor, associated or not with intraocular infammation and with no evidence of degenerative retinal disease. A clinical investigation with detailed anamnesis and laboratory tests should be performed to search for an associated neoplasm. Ophthalmologic and complementary examina- tions such as full-feld electroretinogram, optical coherence tomography, visual feld and fundus autofuorescence, help the diagnosis. Blood tests to search for autoantibodies should be requested. Management consists of prolonged immunosuppression, which may be combined with antioxidant vitamins.
    [Show full text]
  • Melanoma-Associated Retinopathy a Paraneoplastic Autoimmune Complication
    CLINICAL SCIENCES Melanoma-Associated Retinopathy A Paraneoplastic Autoimmune Complication Ying Lu, MD, PhD; Lin Jia, MS; Shirley He, MD, MS; Mary C. Hurley, MS; Monique J. Leys, MD; Thiran Jayasundera, MD; John R. Heckenlively, MD Objectives: To study 11 patients with melanoma- patients (9 of 11) had a strong family history of autoim- associated retinopathy (MAR) to clarify the reliability of mune disorders. Any type of melanoma (cutaneous, cho- various methods of diagnostic testing, to determine the roidal, ciliary body, or choroidal nevi) may be associ- underlying antigenic retinal proteins, and to study the ated with this paraneoplastic autoimmune reactivity. MAR clinical histories and types of associated melanomas. may precede or follow the diagnosis of melanoma. Pa- tients with MAR have the same antigenic retinal pro- Methods: Clinical data were obtained from patients with teins that have been associated with cancer-associated reti- melanoma who developed marked visual problems. Test- nopathy. In addition, 2 new antigenic retinal proteins, ing included electroretinography, kinetic visual fields, aldolase A and aldolase C, were found. comparative studies of Western blots, and indirect im- munohistologic examination to detect antiretinal anti- Conclusions: There was a high prevalence of positive bodies, as well as proteomic studies to identify underly- family histories of autoimmune disease in patients with ing antigenic retinal proteins. MAR. To confirm the disorder, multiple clinical and se- rum diagnostic techniques (Western blot or indirect im- Results: Patients with MAR typically have rapid onset of photopsias, scotomata, and loss of central or paracen- munohistologic examination) are needed. Two newly ob- tral vision. Ophthalmoscopy seldom shows significant served antigenic retinal proteins, aldolase A and aldolase changes early, but electroretinograms are abnormal.
    [Show full text]